Phillippine Journal of Internal Medicine最新文献

筛选

英文中文

Use of Convalescent Plasma Therapy among Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Single-Center Experience 2019冠状病毒病(COVID-19)住院患者恢复期血浆治疗的使用:单中心体验

Phillippine Journal of Internal Medicine Pub Date : 2021-02-17 DOI: 10.1101/2021.02.16.21251824

F. Mesina, Claudette G. Mangahas, Ellen M. Gatchalian, Mary Sheila Ariola-Ramos, Rosalio P. Torres

{"title":"Use of Convalescent Plasma Therapy among Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Single-Center Experience","authors":"F. Mesina, Claudette G. Mangahas, Ellen M. Gatchalian, Mary Sheila Ariola-Ramos, Rosalio P. Torres","doi":"10.1101/2021.02.16.21251824","DOIUrl":"https://doi.org/10.1101/2021.02.16.21251824","url":null,"abstract":"ABSTRACT: COVID-19 Disease has strained our healthcare system. Convalescent plasma has been used to treat emerging infectious diseases - Influenza A/B, SARS-CoV, Ebola virus and now SARS-CoV 2. OBJECTIVE: This study aims to determine the outcome and clinical course of COVID-19 patients who received convalescent plasma transfusion at Cardinal Santos Medical Center. METHODS: This is a retrospective cohort analytical study of 75 patients who received convalescent plasma. RESULTS: Median time from admission to CP transfusion was 3 days. Majority of patients received additional therapies including dexamethasone (100%); Remdesivir (95%); antibiotics (100%), tocilizumab (65%); hemoperfusion (88%) or combination of these. Among the survivors, the median LOS was 15 days while non-survivors have a median LOS of 6 days. One patient (1.33%) had mild transfusion reaction. Four patients (5.33%) developed DVT despite anti-coagulation. There was improvement in the inflammatory markers (LDH pvalue 0.04, CRP pvalue 0.00, Ferritin pvalue 0.0001). There was improvement in the pulmonary parameters - increase in mean PaO2, mean SaO2, and mean PFR; and decrease in mean FiO2 and mean RR post-treatment. Median LOS is 14 days for the CP group vs 11 days for the non-CP group. Mortality rate among the CP group is 25.33% while the non-CP group was 26.67%. LOS and mortality rate did not reach statistical significance. CONCLUSIONS: There was no significant difference in mortality and length of hospital stay in patients given CP vs controls. CP might have a role in the improvement of inflammatory markers and pulmonary status.","PeriodicalId":38775,"journal":{"name":"Phillippine Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81494708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6